Halting progressive neurodegeneration in advanced retinitis pigmentosa

Journal of Clinical Investigation

Volumn 125, Issue 9, 2015, Pages 3704-3713

  Koch, Susanne F ^a,b   Tsai, Yi Ting ^a,b,c   Duong, Jimmy K ^d   Wu, Wen Hsuan ^a,b   Hsu, Chun Wei ^a,b   Wu, Wei Pu ^a,b   Bonet Ponce, Luis ^e   Lin, Chyuan Sheng ^f   Tsang, Stephen H ^a,b,c,f  

^a Howard Hughes Medical Institute   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d Mailman School of Public Health   (United States)

^e UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^f New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

A WAVE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; B WAVE; BLASTOCYST; CONTROLLED STUDY; DISEASE COURSE; ELECTRORETINOGRAM; EMBRYO; EMBRYONIC STEM CELL; FEMALE; MISSENSE MUTATION; MOUSE; NERVE DEGENERATION; NONHUMAN; PHOTORECEPTOR; PHOTORECEPTOR CELL; POINT MUTATION; PRIORITY JOURNAL; REPORTER GENE; RETINITIS PIGMENTOSA; SOUTHERN BLOTTING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; MICE; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; RETINITIS PIGMENTOSA; TRANSDUCTION, GENETIC;

EID: 84941711866     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82462     Document Type: Article

References (51)

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809.
2. Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 1993;34(5):1659-1676.
3. Davis RJ, et al. Therapeutic margins in a novel preclinical model of retinitis pigmentosa. J Neurosci. 2013;33(33):13475-13483.
4. Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci. 2013;36:467-488.
5. Petrs-Silva H, Linden R. Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol. 2014;8:127-136.
6. Thompson DA, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci. 2015;56(2):918-931.
7. Mitamura Y, Mitamura-Aizawa S, Nagasawa T, Katome T, Eguchi H, Naito T. Diagnostic imaging in patients with retinitis pigmentosa. J Med Invest. 2012;59(1-2):1-11.
8. Cepko CL, Vandenberghe LH. Retinal gene therapy coming of age. Hum Gene Ther. 2013;24(3):242-244.
9. McLaughlin ME, Ehrhart TL, Berson EL, Dryja TP. Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci U S A. 1995;92(8):3249-3253.
10. Avila-Fernandez A, et al. Mutation analysis of 272 Spanish families affected by autosomal recessive retinitis pigmentosa using a genotyping microarray. Mol Vis. 2010;16:2550-2558.
11. Huang SH, Pittler SJ, Huang X, Oliveira L, Berson EL, Dryja TP. Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. Nat Genet. 1995;11(4):468-471.
12. Hart AW, et al. Genotype-phenotype correlation of mouse pde6b mutations. Invest Ophthalmol Vis Sci. 2005;46(9):3443-3450.
13. Davis RJ, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q). Invest Ophthalmol Vis Sci. 2008;49(11):5067-5076.
14. Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR. Retinal degeneration mutants in the mouse. Vision Res. 2002;42(4):517-525.
15. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21(1):70-71.
16. Furukawa A, Koike C, Lippincott P, Cepko CL, Furukawa T. The mouse Crx 5′-upstream transgene sequence directs cell-specific and developmentally regulated expression in retinal photoreceptor cells. J Neurosci. 2002;22(5):1640-1647.
17. Young RW. Cell death during differentiation of the retina in the mouse. J Comp Neurol. 1984;229(3):362-373.
18. Swaroop A, Kim D, Forrest D. Transcriptional regulation of photoreceptor development and homeostasis in the mammalian retina. Nat Rev Neurosci. 2010;11(8):563-576.
19. Wert KJ, Lin JH, Tsang SH. General pathophysiology in retinal degeneration. Dev Ophthalmol. 2014;53:33-43.
20. Dejneka NS, et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther. 2004;9(2):182-188.
21. Bennicelli J, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther. 2008;16(3):458-465.
22. Clarke G, et al. A one-hit model of cell death in inherited neuronal degenerations. Nature. 2000;406(6792):195-199.
23. Bainbridge JW, et al. Effect of gene therapy on visual function in Lebers congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239.
24. Cideciyan AV, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009;20(9):999-1004.
25. Maguire AM, et al. Age-dependent effects of RPE65 gene therapy for Lebers congenital amaurosis: A phase 1 dose-escalation trial. Lancet. 2009;374(9701):1597-1605.
26. Simonelli F, et al. Gene therapy for Lebers congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2010;18(3):643-650.
27. Jacobson SG, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9-24.
28. Bennett J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra115.
29. Ashtari M, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest. 2011;121(6):2160-2168.
30. Testa F, et al. Three-year follow-up after unilateral subretinal delivery of adeno-Associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013;120(6):1283-1291.
31. Cideciyan AV, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013;110(6):E517-E525.
32. Bainbridge JW, et al. Long-Term effect of gene therapy on Lebers congenital amaurosis. N Engl J Med. 2015;372(20):1887-1897.
33. Jacobson SG, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920-1926.
34. Wright AF. Long-Term effects of retinal gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1954-1955.
35. Sarra GM, et al. Gene replacement therapy in the retinal degeneration slow (rds) mouse: The effect on retinal degeneration following partial transduction of the retina. Hum Mol Genet. 2001;10(21):2353-2361.
36. Koch S, et al. Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa. Hum Mol Genet. 2012;21(20):4486-4496.
37. Wert KJ, Davis RJ, Sancho-Pelluz J, Nishina PM, Tsang SH. Gene therapy provides long-Term visual function in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet. 2013;22(3):558-567.
38. Mowat FM, et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther. 2013;20(5):545-555.
39. Sahel JA. Saving cone cells in hereditary rod diseases: A possible role for rod-derived cone viability factor (RdCVF) therapy. Retina. 2005;25(8 suppl):S38-S39.
40. Peng B, Xiao J, Wang K, So KF, Tipoe GL, Lin B. Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J Neurosci. 2014;34(24):8139-8150.
41. Shen S, Sujirakul T, Tsang SH. Next-generation sequencing revealed a novel mutation in the gene encoding the beta subunit of rod phosphodiesterase. Ophthalmic Genet. 2014;35(3):142-150.
42. Vandenberghe LH, Auricchio A. Novel adenoassociated viral vectors for retinal gene therapy. Gene Ther. 2012;19(2):162-168.
43. Khani SC, et al. AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci. 2007;48(9):3954-3961.
44. Dalkara D, et al. In vivo-directed evolution of a new adeno-Associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5(189):189ra176.
45. Lin TC, Hsu CC, Chien KH, Hung KH, Peng CH, Chen SJ. Retinal stem cells and potential cell transplantation treatments. J Chin Med Assoc. 2014;77(11):556-561.
46. Busskamp V, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science. 2010;329(5990):413-417.
47. Jacobson SG, Sumaroka A, Luo X, Cideciyan AV. Retinal optogenetic therapies: clinical criteria for candidacy. Clin Genet. 2013;84(2):175-182.
48. Weiland JD, Humayun MS. Retinal prosthesis. IEEE Trans Biomed Eng. 2014;61(5):1412-1424.
49. Sancho-Pelluz J, et al. Mice with a D190N mutation in the gene encoding rhodopsin: A model for human autosomal-dominant retinitis pigmentosa. Mol Med. 2012;18:549-555.
50. Tsang SH, et al. Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase. Science. 1996;272(5264):1026-1029.
51. Tsang SH, et al. Role for the target enzyme in deactivation of photoreceptor G protein in vivo. Science. 1998;282(5386):117-121.